Candriam SCA’s Oric Pharmaceuticals ORIC Stock Holding History

Candriam SCA’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.27M	Buy	+574,085	New	+$6.52M	0.04%	333

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Candriam SCA's ORIC Position: Q1 2026 in Review

Candriam SCA opened a new position in Oric Pharmaceuticals (ORIC) in Q1 2026: 574,085 shares worth $7.27M. The stake represents 0.04% of the portfolio and ranks #333 among its holdings.

182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

Candriam SCA held 574,085 shares of Oric Pharmaceuticals worth $7.27M as of Q1 2026.
Oric Pharmaceuticals was a new Candriam SCA position in Q1 2026.
Oric Pharmaceuticals made up 0.04% of Candriam SCA's portfolio in Q1 2026, its #333 holding.
182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.